AMGN vs. TECH: Amgen vs. Bio-Techne Stock Comparison

Company Profile

Amgen (AMGN) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while TECH is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Amgen (AMGN) at 78.35% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Amgen (AMGN) at 24.14% keeps the most of each sales dollar — above its industry’s net margin range — and Bio-Techne (TECH) at 14.00% also retains a top-quartile share.

Amgen (AMGN) at 35.79% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Amgen (AMGN) at 9.95% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Amgen (AMGN) at 88.23% and Bio-Techne (TECH) at 152.17% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Growth Metrics

Financial Strength

Both Amgen (AMGN) at 1.48 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Bio-Techne (TECH) at 0.13 is near its industry mid-range for debt-to-equity ratio, while Amgen (AMGN) at 3.76 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Both Amgen (AMGN) at 2.16% and Bio-Techne (TECH) at 0.44% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Amgen (AMGN) at 57.62% and Bio-Techne (TECH) at 27.59% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Amgen (AMGN) at 26.69 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Amgen (AMGN) at 6.40 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Bio-Techne (TECH) at 5.28 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.

Valuation Metrics